MKP1 mediates resistance to therapy in HER2-positive breast tumors
MKP1 mediates resistance to therapy in HER2-positive breast tumors
复制标题
DOI：
10.1080/23723556.2014.997518
复制
发表时间：
2015-01-01
影响因子：
2.1
通讯作者：
Li, Jian Jian
中科院分区：
文献类型：
--
作者：
Candas, Demet;Li, Jian Jian
丝裂原活化蛋白激酶磷酸酶1（MKP 1或DUSP1）是一种抗凋亡磷酸酶，在许多癌症中过表达，包括乳腺癌。MKP 1表达在放射处理的乳腺癌细胞中是可诱导的，并且与人表皮生长因子受体2（ERBB 2，HER2）表达相关。MKP 1在治疗耐药性中的作用表明，在HER2阳性乳腺肿瘤中靶向MKP 1可能会显著增强抗HER2和其他抗癌疗法的疗效。
Mitogen-activated protein kinase phosphatase 1 (MKP1 or DUSP1) is an antiapoptotic phosphatase that is overexpressed in many cancers, including breast cancer. MKP1 expression is inducible in radiation-treated breast cancer cells, and correlates with human epidermal growth factor receptor 2 (ERBB2, HER2) expression. The role of MKP1 in therapy resistance suggests that targeting MKP1 in HER2-positive breast tumors may significantly enhance the efficacy of anti-HER2 and other anticancer therapies.